Lineage Cell Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M |
| Gross profit | — | — | $8.3M | $14.0M | $2.9M |
| Operating income | -$36.6M | -$21.5M | -$24.7M | -$22.5M | -$49.2M |
| Operating expenses | — | — | $33.0M | $36.5M | $52.1M |
| Cost of revenue | — | $334,000 | $671,000 | $728,000 | $1.4M |
| Cash from operations | -$18.9M | -$23.1M | -$28.6M | $1.1M | -$23.6M |
| Capital expenditure | $522,000 | $565,000 | $674,000 | $413,000 | $340,000 |
| Free cash flow | -$19.4M | -$23.7M | -$29.2M | $646,000 | -$23.9M |
| Impairments | $14.8M | $0 | $0 | $0 | — |
| Total assets | $112.6M | $113.2M | $101.0M | $123.7M | $174.5M |
| Total liabilities | $69.2M | $36.2M | $39.0M | $51.7M | $83.6M |
Shares outstanding 249.3M · Free float 45.4%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.